NEW YORK, Sept. 20, 2013 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential securities fraud at OvaScience, Inc. ("OvaScience" or the "Company") (NASDAQ: OVAS).
The investigation focuses on whether the Company and its executives violated federal securities laws with respect to its disclosures concerning business, operational, and compliance policies.
Specifically, the investigation focuses on whether OvaScience misrepresented to the FDA and the investing public that its AUGMENT technology qualified for 361 HCT/P designation and therefore did not need FDA licensure in order to be tested and marketed.
On September 10, 2013, the Company announced that it would suspend enrollment of AUGMENT in the U.S. after receiving an "untitled" letter from the FDA questioning the designation of AUGMENT as 361 HCT/P.
Following this news, OvaScience's stock declined by $3.32 or over 23%.
Request more information now by clicking here: www.faruqilaw.com/OVAS. There is no cost or obligation to you.
If you invested in OvaScience stock or options between February 25, 2013 and September 10, 2013 and would like to discuss your legal rights, visit www.faruqilaw.com/OVAS. You can also contact us by calling Richard Gonnello or Francis McConville toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to firstname.lastname@example.org or email@example.com. Faruqi & Faruqi, LLP also encourages anyone with information regarding OvaScience's conduct to contact the firm, including whistleblowers, former employees, shareholders and others.
Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.
FARUQI & FARUQI, LLP
369 Lexington Avenue, 10th Floor
New York, NY 10017
Attn: Richard Gonnello, Esq.
Francis McConville, Esq.
Telephone: (877) 247-4292 or (212) 983-9330
|SOURCE Faruqi & Faruqi, LLP|
Copyright©2012 PR Newswire.
All rights reserved